OHIO STATE UNIVERSITY
Development of Improved HIV-1 Capsid Inhibitors
Development of Improved HIV-1 Capsid Inhibitors is a funding opportunity from OHIO STATE UNIVERSITY, up to 196175, closing December 31, 2026.
Dec 31, 2026
(154d left)Overview
ABSTRACT The HIV-1 capsid protein (CA) is an attractive target for the development of novel antiretrovirals due to its essential and multifaceted roles in the virus biology. Lenacapavir (LEN) is a recently discovered first-in-class, long-acting capsid-targeting inhibitor with picomolar potency against HIV-1. Phase 2/3…